Determinants of liver fat composition in overweight and obese humans

Determinants of liver fat composition in overweight and obese humans - Determinants of liver fat composition

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45290

Enrollment

Registered

2017-05-18

Start date

2017-08-15

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver Non-alcoholic fatty liver (NAFL)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Signed informed consent Caucasian (people will be excluded when having a 50% or more then 50% racial African/Asian background) Male or postmenopausal female Aged 45-70 years at start of the study Body mass index (BMI) 27 * 35 kg/m2 Stable dietary habits (no weight loss or gain >3kg in the past 3 months) Sedentary lifestyle (not more than 2 hours of sports per week)

Exclusion criteria

Exclusion criteria: Type 2 diabetes Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other) Contra-indication for MRI Alcohol consumption of >2 servings per day Smoking >5 cigarettes per day Use of anti-coagulants

Design outcomes

Primary

Measure	Time frame
- %SFA expressed as relative amount of SFA to the total amount of fatty acids. - DNL expressed as percentage of palmitate in very-low-density-lipoprotein (VLDL)-TG originating from DNL	—

Secondary

Measure	Time frame
- Liver fat composition expressed as relative amount of MUFA and PUFA to the total amount of fatty acids, in addition to %SFA - Adipose tissue fat composition expressed as relative amount of SFA, MUFA and PUFA to the total amount of fatty acids - Adipose tissue fat composition expressed as relative amount of linoleic acid, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) to the total amount of fatty acids. - Hepatic, peripheral and whole body insulin sensitivity expressed as % suppression of endogenous glucose production (EGP), rate of disappearance (Rd) in mol/kg/min and glucose infusion rate (GIR) in mol/kg/min. - Muscle insulin sensitivity expressed as determinants/markers for muscle insulin sensitivity in muscle biopsy (oxphos, GLUT4, intramyocellular lipids (IMCL).	—

Measure

Time frame

- Liver fat composition expressed as relative amount of MUFA and PUFA to the total amount of fatty acids, in addition to %SFA - Adipose tissue fat composition expressed as relative amount of SFA, MUFA and PUFA to the total amount of fatty acids - Adipose tissue fat composition expressed as relative amount of linoleic acid, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) to the total amount of fatty acids. - Hepatic, peripheral and whole body insulin sensitivity expressed as % suppression of endogenous glucose production (EGP), rate of disappearance (Rd) in *mol/kg/min and glucose infusion rate (GIR) in *mol/kg/min. - Muscle insulin sensitivity expressed as determinants/markers for muscle insulin sensitivity in muscle biopsy (oxphos, GLUT4, intramyocellular lipids (IMCL).

—

Countries

Netherlands

Outcome results